These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 9135737)

  • 1. Safety studies of the intraperitoneal injection of E1A--liposome complex in mice.
    Xing X; Liu V; Xia W; Stephens LC; Huang L; Lopez-Berestein G; Hung MC
    Gene Ther; 1997 Mar; 4(3):238-43. PubMed ID: 9135737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer.
    Chang JY; Xia W; Shao R; Sorgi F; Hortobagyi GN; Huang L; Hung MC
    Oncogene; 1997 Feb; 14(5):561-8. PubMed ID: 9053854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety study and characterization of E1A-liposome complex gene-delivery protocol in an ovarian cancer model.
    Xing X; Zhang S; Chang JY; Tucker SD; Chen H; Huang L; Hung MC
    Gene Ther; 1998 Nov; 5(11):1538-44. PubMed ID: 9930307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liposome-mediated in vivo E1A gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER-2/neu.
    Yu D; Matin A; Xia W; Sorgi F; Huang L; Hung MC
    Oncogene; 1995 Oct; 11(7):1383-8. PubMed ID: 7478560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of intratumoral liposome E1A gene therapy in patients with recurrent breast and head and neck cancer.
    Yoo GH; Hung MC; Lopez-Berestein G; LaFollette S; Ensley JF; Carey M; Batson E; Reynolds TC; Murray JL
    Clin Cancer Res; 2001 May; 7(5):1237-45. PubMed ID: 11350889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway.
    Ueno NT; Bartholomeusz C; Herrmann JL; Estrov Z; Shao R; Andreeff M; Price J; Paul RW; Anklesaria P; Yu D; Hung MC
    Clin Cancer Res; 2000 Jan; 6(1):250-9. PubMed ID: 10656456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER-2/neu-targeting cancer therapy via adenovirus-mediated E1A delivery in an animal model.
    Zhang Y; Yu D; Xia W; Hung MC
    Oncogene; 1995 May; 10(10):1947-54. PubMed ID: 7761095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Technology evaluation: tgDCC-E1A, targeted genetics/MD Anderson.
    Wagner JA
    Curr Opin Mol Ther; 1999 Apr; 1(2):266-70. PubMed ID: 11715950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of intratracheal lung cancer development by systemic delivery of E1A.
    Chang JY; Xia W; Shao R; Hung MC
    Oncogene; 1996 Oct; 13(7):1405-12. PubMed ID: 8875978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A.
    Yu D; Wolf JK; Scanlon M; Price JE; Hung MC
    Cancer Res; 1993 Feb; 53(4):891-8. PubMed ID: 8094034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutant SV40 large T antigen as a therapeutic agent for HER-2/neu-overexpressing ovarian cancer.
    Xing X; Matin A; Yu D; Xia W; Sorgi F; Huang L; Hung MC
    Cancer Gene Ther; 1996; 3(3):168-74. PubMed ID: 8725881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A.
    Ueno NT; Yu D; Hung MC
    Oncogene; 1997 Aug; 15(8):953-60. PubMed ID: 9285690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon.
    Akbulut H; Zhang L; Tang Y; Deisseroth A
    Cancer Gene Ther; 2003 May; 10(5):388-95. PubMed ID: 12719708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Down regulation of HER2/neu expression by adenovirus E1A and its anti-tumor activity].
    Lu H; Qin H; Zhang Y
    Zhonghua Zhong Liu Za Zhi; 2000 Sep; 22(5):370-3. PubMed ID: 11778270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Issues in the development of gene therapy: preclinical experiments in E1A gene delivery.
    Ueno NT; Xia W; Tucker SD; Zhang S; Lopez-Berestein G; Huang L; Hung MC
    Oncol Rep; 1999; 6(2):257-62. PubMed ID: 10022986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity.
    Irving J; Wang Z; Powell S; O'Sullivan C; Mok M; Murphy B; Cardoza L; Lebkowski JS; Majumdar AS
    Cancer Gene Ther; 2004 Mar; 11(3):174-85. PubMed ID: 14726958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic gene therapy in human xenograft tumor models by liposomal delivery of the E1A gene.
    Ueno NT; Bartholomeusz C; Xia W; Anklesaria P; Bruckheimer EM; Mebel E; Paul R; Li S; Yo GH; Huang L; Hung MC
    Cancer Res; 2002 Nov; 62(22):6712-6. PubMed ID: 12438271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bcl-2 antisense oligonucleotide overcomes resistance to E1A gene therapy in a low HER2-expressing ovarian cancer xenograft model.
    Bartholomeusz C; Itamochi H; Yuan LX; Esteva FJ; Wood CG; Terakawa N; Hung MC; Ueno NT
    Cancer Res; 2005 Sep; 65(18):8406-13. PubMed ID: 16166319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced paclitaxel cytotoxicity and prolonged animal survival rate by a nonviral-mediated systemic delivery of E1A gene in orthotopic xenograft human breast cancer.
    Liao Y; Zou YY; Xia WY; Hung MC
    Cancer Gene Ther; 2004 Sep; 11(9):594-602. PubMed ID: 15272313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. E1A sensitizes HER2/neu-overexpressing Ewing's sarcoma cells to topoisomerase II-targeting anticancer drugs.
    Zhou Z; Jia SF; Hung MC; Kleinerman ES
    Cancer Res; 2001 Apr; 61(8):3394-8. PubMed ID: 11309298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.